SGAM
SCLN

Smith Group Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Smith Group Asset Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-12,140
Closed -$84K – 534
2015
Q3 		$84K Buy
12,140
+1,700
+16% +$14.6K ﹤0.01% 275
2015
Q2 		$103K Buy
10,440
+890
+9% +$8.11K ﹤0.01% 244
2015
Q1 		$85K Buy
9,550
+2,300
+32% +$18.3K ﹤0.01% 303
2014
Q4 		$64K Hold
7,250
– – ﹤0.01% 285
2014
Q3 		$50K Buy
7,250
+4,100
+130% +$24.6K ﹤0.01% 255
2014
Q2 		$17K Hold
3,150
– – ﹤0.01% 315
2014
Q1 		$14K Sell
3,150
-2,760
-47% -$13.3K ﹤0.01% 309
2013
Q4 		$30K Hold
5,910
– – ﹤0.01% 268
2013
Q3 		$30K Buy
+5,910
New +$32.9K ﹤0.01% 268

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sensato Investors San Francisco, California $122M AUM 5.69% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Smith Group Asset Management's SCLN Position: Q4 2015 in Review

Smith Group Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2015, closing a stake of 12,140 shares — an estimated $84K sold.

Smith Group Asset Management first reported a position in SCLN in Q3 2013 and held it in 9 quarters. The position peaked at $103K in Q2 2015. 133 funds tracked by Wall St. Rank hold SCLN as of Q4 2015.

  • Smith Group Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 12,140 Sciclone Pharmaceuticals Inc shares in Q4 2015, an estimated $84K.
  • Smith Group Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and held it in 9 quarters.
  • Smith Group Asset Management's Sciclone Pharmaceuticals Inc position peaked at $103K in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2015.

Based on Smith Group Asset Management's 13F filing for Q4 2015, filed 3 Feb 2016.